Remove Aortic valve Remove Heart Valves Remove TAVR
article thumbnail

Alternative access in transcatheter aortic valve replacement—an updated focused review

Frontiers in Cardiovascular Medicine

Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades.

article thumbnail

Heart-Valve-Surgery.Com and Medtronic Launch Novel "Aortic Stenosis Patient Activation Platform" to Empower Patients

DAIC

Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. To experience the Aortic Stenosis Patient Activation Platform, please click here.

article thumbnail

Heart-Valve-Surgery.Com, Medtronic Launch Novel 'Aortic Stenosis Patient Activation Platform' to Empower Patients

DAIC

Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. As a result, the heart must work "over time" to pump blood throughout the body. To experience the Aortic Stenosis Patient Activation Platform, please click here.

article thumbnail

'Tootsie Roll' Introduced for Leaky Transcatheter Heart Valves

Med Page Today

(MedPage Today) -- Operators reported the initial success of a novel transcatheter technique for treating complex paravalvular leaks (PVLs) after transcatheter aortic valve replacement (TAVR) or transcatheter mitral valve replacement (TMVR) in.

article thumbnail

Challenges and Future Directions in Redo Aortic Valve Reintervention After Transcatheter Aortic Valve Replacement Failure

Circulation: Cardiovascular Interventions

Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Reintervention for failed transcatheter heart valves will likely increase in the future as younger patients are expected to outlive the initial bioprosthesis.

article thumbnail

Randomized Controlled Trial of Myval Transcatheter Heart Valve

American College of Cardiology

The goal of the LANDMARK trial was to evaluate transcatheter aortic valve replacement (TAVR) with the Myval prosthesis compared with a contemporary prosthesis among patients with symptomatic severe aortic stenosis.

article thumbnail

Redo-TAVR with balloon-expandable valves: outcomes from a national registry

Cardiology Update

In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 4.0%, p=0.36) or one year (17.5% vs. 3.3%, p=0.18).

TAVR 52